- Home
- CAC vs MLYS Comparison
CAC vs MLYS Comparison
Compare CAC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAC
- MLYS
- Stock Information
- Founded
- CAC 1875
- MLYS 2019
- Country
- CAC United States
- MLYS United States
- Employees
- CAC N/A
- MLYS N/A
- Industry
- CAC Major Banks
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- CAC Finance
- MLYS Health Care
- Exchange
- CAC Nasdaq
- MLYS Nasdaq
- Market Cap
- CAC N/A
- MLYS 526.1M
- IPO Year
- CAC 1997
- MLYS 2023
- Fundamental
- Price
- CAC $45.85
- MLYS $10.76
- Analyst Decision
- CAC Hold
- MLYS Strong Buy
- Analyst Count
- CAC 3
- MLYS 2
- Target Price
- CAC $48.33
- MLYS $30.00
- AVG Volume (30 Days)
- CAC 87.0K
- MLYS 263.5K
- Earning Date
- CAC 01-28-2025
- MLYS 03-20-2025
- Dividend Yield
- CAC 3.74%
- MLYS N/A
- EPS Growth
- CAC 21.89
- MLYS N/A
- EPS
- CAC 3.62
- MLYS N/A
- Revenue
- CAC $177,396,000.00
- MLYS N/A
- Revenue This Year
- CAC N/A
- MLYS N/A
- Revenue Next Year
- CAC $10.12
- MLYS N/A
- P/E Ratio
- CAC $12.27
- MLYS N/A
- Revenue Growth
- CAC 10.05
- MLYS N/A
- 52 Week Low
- CAC $28.62
- MLYS $8.58
- 52 Week High
- CAC $50.07
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- CAC 51.55
- MLYS 44.53
- Support Level
- CAC $45.00
- MLYS $9.57
- Resistance Level
- CAC $46.49
- MLYS $10.79
- Average True Range (ATR)
- CAC 1.20
- MLYS 0.64
- MACD
- CAC 0.24
- MLYS 0.11
- Stochastic Oscillator
- CAC 48.77
- MLYS 63.98
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.